New Tool for Rapid and Accurate Detection of Interleukin-2 and Soluble Interleukin-2 Receptor a in Cancer Diagnosis Using a Bioresponsive Microgel and Multivalent Protein Binding
- Authors
- Yang, Hae Min; Yim, Bora; Lee, Byung-Hyun; Park, Yongdoo; Kim, Young Gyu; Kim, Jongseong; Yoo, Dongwon
- Issue Date
- 28-Jul-2021
- Publisher
- American Chemical Society
- Keywords
- hydrogel; multivalent protein binding; label-free; rapid detection; cancer diagnosis; biosensor; surface plasmon resonance
- Citation
- ACS Applied Materials and Interfaces, v.13, no.29, pp 33782 - 33789
- Pages
- 8
- Indexed
- SCIE
SCOPUS
- Journal Title
- ACS Applied Materials and Interfaces
- Volume
- 13
- Number
- 29
- Start Page
- 33782
- End Page
- 33789
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/53876
- DOI
- 10.1021/acsami.1c04827
- ISSN
- 1944-8244
1944-8252
- Abstract
- Interleukin-2 (IL-2) and its a receptor in soluble form (sIL-2R alpha) are considered biomarkers for cancers and immune-related diseases. Enzyme-linked immunosorbent assay is the most common method used to evaluate biomarkers in clinical practice; it is precise but time-consuming and involves complicated procedures. Here, we have developed a rapid yet accurate modality for cancer diagnosis that enables on-site evaluation of cancer markers, that is, IL-2 and sIL-2R alpha, without complicated pretreatment of cancer patient-derived blood samples. Surface plasmon resonance and bioresponsive microgels conjugated with IL-2 receptors, that is, IL-2R beta and IL-2R gamma, were utilized to measure IL-2 and sIL-2R alpha levels via multivalent protein binding (MPB) between the ligands and their receptors. Our results showed that this novel method enables us to perform cancer diagnosis with a 1000-fold dilution of serum in 10 min. The advantage of MPB-based cancer diagnosis originates from its great selectivity for a target molecule and tolerance to a myriad of nonspecific substances in serum, which allows on-site clinical evaluation. Importantly, our finding implies that MPB-based cancer diagnosis provides a new paradigm not only for improving cancer treatment but also for evaluating a target molecule in unpurified and complex solutions such as blood.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 4. Research institute > Stem Cell Institute > 1. Journal Articles
- 1. Basic Science > Department of Biomedical Engineering > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.